On November 25, 2019 Inovio Pharmaceuticals, Inc. (NASDAQ: INO) reported that Dr. J. Joseph Kim, President and CEO, will present in a fireside discussion at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 12:30 p.m. Eastern Time in New York, NY (Press release, Inovio, NOV 25, 2019, View Source [SID1234551641]). Dr. Kim will provide an Inovio overview and business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside discussion will be webcast live and may be accessed by visiting Inovio’s website at View Source Archived versions of the presentations will be made available through the Inovio Investor Relations Events page.

On November 25, 2019 Bio-Techne Corporation (NASDAQ: TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the Evercore ISI 2nd Annual HealthCONx Conference on Wednesday, December 4, 2019 at 11:45 a.m. EST (Press release, Bio-Techne, NOV 25, 2019, View Sourcepress-releases/detail/167/bio-techne-to-present-at-the-evercore-isi-2nd-annual" target="_blank" title="View Sourcepress-releases/detail/167/bio-techne-to-present-at-the-evercore-isi-2nd-annual" rel="nofollow">View Source [SID1234551658]). The conference will be held at the Four Seasons hotel in Boston, MA. A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 25, 2019 Mylan N.V. (NASDAQ: MYL) reported that it will present at the Evercore ISI HealthCONx Conference in Boston on Tuesday, Dec. 3, 2019 at 11 a.m. ET (Press release, Mylan, NOV 25, 2019, https://www.prnewswire.com/news-releases/mylan-to-present-at-the-evercore-isi-healthconx-conference-300964141.html [SID1234551672]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live webcast of the presentation via the investor relations section of Mylan’s website at investor.mylan.com. An archived version also will be available following the live presentation and can be accessed at the same location for a limited time.

On November 25, 2019 Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, reported the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), seeking approval for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed or refractory follicular lymphoma (FL) (Press release, Verastem, NOV 25, 2019, View Source [SID1234551659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We have seen the significant benefit of COPIKTRA as a treatment option for patients throughout our clinical trials and experience globally," said Brian Stuglik, Chief Executive Officer of Verastem Oncology. "The MAA submission for COPIKTRA in Europe is an important milestone in our mission to offer new therapies to patients in need and we are committed to working effectively with the EMA through the regulatory process to bring COPIKTRA to patients in Europe."

On November 25, 2019 Luminex Corporation (NASDAQ: LMNX) reported that Harriss Currie, Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 in New York, NY (Press release, Luminex, NOV 25, 2019, View Source [SID1234551671]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Luminex’s presentation will be available at 10:30 a.m. Eastern Time on Wednesday, December 4th and may be accessed at Luminex Corporation’s website at investor.luminexcorp.com. The presentation will be archived for six months on the website using the ‘replay’ link.